OTHER INFORMATION
+Added: On May 2, 2023, the Company and Amgen agreed to terminate the Amgen Agreement in accordance with its terms, effective on such date.
+Added: Neither party incurred any termination penalty or fees in connection with the termination of the Amgen Agreement.
+Added: A brief description of the Amgen Agreement is set forth under the heading “Amgen Research Collaboration and License Agreement” contained in Part I, Item 2 of this Quarterly Report, and such description is incorporated by reference in this Item 5.
Description of Exhibits
−Removed: Mutual Separation Agreement, dated July 13, 2022, by and between Entera Bio Ltd.
−Removed: Spiros Jamas (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on July 18, 2022 and incorporated herein by reference).
−Removed: Amended and Restated Employment Agreement, dated July 15, 2022 between Entera Bio Ltd.
−Removed: and Miranda J.
−Removed: Toledano (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on July 18, 2022 and incorporated herein by reference).
−Removed: Sales Agreement, dated September 2, 2022, by and between Entera Bio Ltd.
−Removed: and SVB Securities LLC (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on September 2, 2022 and incorporated herein by reference).
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
11 unchanged sentences
Cover Page Interactive Data File (embedded within the Inline XBRL document)
−Removed: * Management contract or compensation plan or arrangement
−Removed: ** Pursuant to Item 601(a)(5) of Regulation S-K, schedules and similar attachments to this exhibit have been omitted because they do not contain information material to an investment or voting decision and such information is not otherwise disclosed in such exhibit.
−Removed: The Company will supplementally provide a copy of any omitted schedule or similar attachment to the U.S.
−Removed: Securities and Exchange Commission or its staff upon request.
+Added: * Furnished herewith.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
ENTERA BIO LTD.
−Removed: November 10, 2022
−Removed: /s/ Miranda J.
+Added: /s/ Miranda Toledano
+Added: Miranda Toledano
Chief Executive Officer
(Principal Executive Officer)
−Removed: November 10, 2022
/s/ Dana Yaacov-Garbeli
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.